Ryan C. Widau

1.2k total citations
31 papers, 468 citations indexed

About

Ryan C. Widau is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Ryan C. Widau has authored 31 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 15 papers in Oncology and 10 papers in Epidemiology. Recurrent topics in Ryan C. Widau's work include Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Liver Disease Diagnosis and Treatment (8 papers). Ryan C. Widau is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Liver Disease Diagnosis and Treatment (8 papers). Ryan C. Widau collaborates with scholars based in United States, Germany and Japan. Ryan C. Widau's co-authors include David Ferry, Patricia J. Gallagher, Richard A. Walgren, Nicolas Penel, Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Jin Jin, Akash D. Parekh, Roy S. Herbst and Nikolai N. Khodarev and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Ryan C. Widau

30 papers receiving 463 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan C. Widau United States 10 214 152 141 127 99 31 468
Yufu Ye China 12 155 0.7× 122 0.8× 151 1.1× 155 1.2× 130 1.3× 26 516
Vito Longo Italy 12 284 1.3× 127 0.8× 95 0.7× 65 0.5× 82 0.8× 29 487
Irene Lo China 7 147 0.7× 198 1.3× 123 0.9× 71 0.6× 100 1.0× 9 467
Laura Torrens Spain 5 144 0.7× 85 0.6× 38 0.3× 117 0.9× 121 1.2× 6 340
Marissa Teo Singapore 5 375 1.8× 67 0.4× 207 1.5× 44 0.3× 62 0.6× 6 515
Yun Hua Lee Singapore 5 291 1.4× 97 0.6× 212 1.5× 78 0.6× 259 2.6× 5 571
Li-Xi Huang China 12 429 2.0× 195 1.3× 349 2.5× 69 0.5× 65 0.7× 13 691
Shi-Ping Chen China 12 392 1.8× 156 1.0× 377 2.7× 56 0.4× 55 0.6× 14 645
Lili Tao China 12 168 0.8× 77 0.5× 155 1.1× 67 0.5× 40 0.4× 31 399
Dinglan Zuo China 14 100 0.5× 249 1.6× 57 0.4× 76 0.6× 187 1.9× 25 534

Countries citing papers authored by Ryan C. Widau

Since Specialization
Citations

This map shows the geographic impact of Ryan C. Widau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan C. Widau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan C. Widau more than expected).

Fields of papers citing papers by Ryan C. Widau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan C. Widau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan C. Widau. The network helps show where Ryan C. Widau may publish in the future.

Co-authorship network of co-authors of Ryan C. Widau

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan C. Widau. A scholar is included among the top collaborators of Ryan C. Widau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan C. Widau. Ryan C. Widau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iyer, Gopa, Hiromichi Ebi, Natalie Cook, et al.. (2025). A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.. Journal of Clinical Oncology. 43(5_suppl). 662–662. 4 indexed citations
2.
Llovet, Josep M., Amit G. Singal, Augusto Villanueva, et al.. (2022). Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clinical Cancer Research. 28(11). 2297–2305. 13 indexed citations
3.
4.
Finn, Richard S., Thomas Yau, Chih‐Hung Hsu, et al.. (2022). Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2.. Journal of Clinical Oncology. 40(4_suppl). 423–423. 5 indexed citations
5.
Kudo, Masatoshi, Richard S. Finn, Manabu Morimoto, et al.. (2021). Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer. 10(5). 451–460. 9 indexed citations
6.
7.
8.
Galle, Peter R., Masatoshi Kudo, Josep M. Llovet, et al.. (2020). Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2. Journal of Hepatology. 73. S386–S387. 1 indexed citations
9.
Zhu, Andrew X., Masafumi Ikeda, Peter R. Galle, et al.. (2020). Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites.. Journal of Clinical Oncology. 38(15_suppl). 4644–4644. 1 indexed citations
10.
Reig, María, Peter R. Galle, Masatoshi Kudo, et al.. (2020). Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver International. 41(3). 598–607. 14 indexed citations
11.
12.
13.
14.
Rañoa, Diana Rose E., Ryan C. Widau, Stephen Mallon, et al.. (2018). STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability. Cancer Research. 79(7). 1465–1479. 75 indexed citations
15.
Arkenau, Hendrik‐Tobias, Juan Martín-Liberal, Emiliano Calvo, et al.. (2018). Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). The Oncologist. 23(12). 1407–e136. 123 indexed citations
16.
Reck, Martin, Edward B. Garon, Luis Paz‐Ares, et al.. (2017). Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clinical Lung Cancer. 19(3). 213–220.e4. 12 indexed citations
17.
Spiotto, Michael T., et al.. (2013). Animal Models to Study the Mutational Landscape for Oral Cavity and Oropharyngeal Cancers. SHILAP Revista de lepidopterología. 4(1). e1–e1. 5 indexed citations
18.
Widau, Ryan C., Yanbin Zheng, Caroline Y. Sung, et al.. (2012). p19Arf Represses Platelet-Derived Growth Factor Receptor β by Transcriptional and Posttranscriptional Mechanisms. Molecular and Cellular Biology. 32(21). 4270–4282. 13 indexed citations
19.
Zhang, Liguo, Ryan C. Widau, B. Paul Herring, & Patricia J. Gallagher. (2011). Delta-like 1-Lysine613 regulates notch signaling. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1813(12). 2036–2043. 8 indexed citations
20.
Widau, Ryan C., Yijun Jin, Shelley A.H. Dixon, Brian E. Wadzinski, & Patricia J. Gallagher. (2010). Protein Phosphatase 2A (PP2A) Holoenzymes Regulate Death-associated Protein Kinase (DAPK) in Ceramide-induced Anoikis. Journal of Biological Chemistry. 285(18). 13827–13838. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yufu Ye Breakdown of academic impact, for papers by Vito Longo Breakdown of academic impact, for papers by Irene Lo Breakdown of academic impact, for papers by Laura Torrens Breakdown of academic impact, for papers by Marissa Teo Breakdown of academic impact, for papers by Yun Hua Lee Breakdown of academic impact, for papers by Li-Xi Huang Breakdown of academic impact, for papers by Shi-Ping Chen Breakdown of academic impact, for papers by Lili Tao Breakdown of academic impact, for papers by Dinglan Zuo
Rankless by CCL
2026